OKYO Pharma Limited (OKYO)
- Previous Close
1.4600 - Open
1.4900 - Bid 1.3700 x 100
- Ask 1.4800 x 100
- Day's Range
1.3571 - 1.4900 - 52 Week Range
0.9200 - 3.0700 - Volume
9,100 - Avg. Volume
71,455 - Market Cap (intraday)
49.189M - Beta (5Y Monthly) -3.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6100 - Earnings Date Aug 13, 2024 - Aug 19, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.
www.okyopharma.comRecent News: OKYO
Performance Overview: OKYO
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OKYO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OKYO
Valuation Measures
Market Cap
48.52M
Enterprise Value
46.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.59
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-173.43%
Return on Equity (ttm)
-2,968.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-13.27M
Diluted EPS (ttm)
-0.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
4.05M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.77M
Research Analysis: OKYO
Company Insights: OKYO
OKYO does not have Company Insights